Share via

In 2003, Kelly Martin was hired to turn around Elan Corporation, the Irish
biotechnology company then laid low by an accounting scandal and stalled
drug development. Nearly nine, turbulent years later and only six months
before he steps down as chief executive, there are the clearest signals yet
of success.

Plans to be unveiled today to create The Cambridge-Elan Centre for Research
Innovation underline Mr Martin’s determination to refocus Elan on drug
discovery for three diseases: multiple sclerosis, Alzheimer’s and
Parkinson’s.